
Rhenium (Re186) Obisbemeda Shows Initial Safety, Clinical Benefit in Leptomeningeal Metastases
Single-dose rhenium (Re186) obisbemeda (Reyobiq; 186RNL) was well tolerated and has demonstrated early clinical benefit in patients with leptomeningeal metastases, according to data from the phase 1 dose-escalation ReSPECT-LM trial (NCT05034497).1,2 Data …